TianYu Bio-Technology Co., Ltd. (SHA:603717)
China · Delayed Price · Currency is CNY 7.05
+0.20 (2.92%)
May 22, 2026, 3:00 PM CST
TianYu Bio-Technology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 654.22 | 725.59 | 794.5 | 668.39 | 940.87 | 633.77 |
Other Revenue | - | - | 7 | 2.06 | 4.04 | 4.31 |
| 654.22 | 725.59 | 801.51 | 670.45 | 944.91 | 638.08 | |
Revenue Growth (YoY) | -19.79% | -9.47% | 19.55% | -29.05% | 48.09% | 9.53% |
Cost of Revenue | 680.26 | 726.5 | 732.8 | 990.07 | 859.29 | 588.92 |
Gross Profit | -26.04 | -0.91 | 68.71 | -319.62 | 85.62 | 49.16 |
Selling, General & Admin | 81.98 | 84.08 | 110 | 95.41 | 88.53 | 97.09 |
Research & Development | 11.58 | 13.92 | 11.29 | 13.91 | 26.38 | 10.37 |
Other Operating Expenses | -1.28 | -0.91 | 2.13 | 1.35 | 7.61 | 3.98 |
Operating Expenses | 92.27 | 97.1 | 145.43 | 114.76 | 354.67 | 283.67 |
Operating Income | -118.31 | -98 | -76.72 | -434.38 | -269.05 | -234.52 |
Interest Expense | - | - | -36.53 | -30.56 | -29.18 | -48.76 |
Interest & Investment Income | 16.83 | - | 29.9 | 11.67 | 19.71 | 37.52 |
Currency Exchange Gain (Loss) | - | - | 0.09 | 0 | - | - |
Other Non Operating Income (Expenses) | -3.39 | -5.79 | -1.27 | -0.51 | -31.16 | -9.28 |
EBT Excluding Unusual Items | -104.88 | -103.79 | -84.54 | -453.77 | -309.68 | -255.04 |
Impairment of Goodwill | - | - | -5 | - | - | - |
Gain (Loss) on Sale of Investments | 7.88 | 4.52 | -0.43 | -109.7 | -25.28 | - |
Gain (Loss) on Sale of Assets | 1.87 | 25.97 | -0.67 | 0.99 | 47.44 | 8.81 |
Asset Writedown | -35.19 | -22.93 | -2.92 | -14.97 | -1.4 | -0.41 |
Other Unusual Items | - | - | 2.23 | -3.85 | 9.78 | 10.94 |
Pretax Income | -130.32 | -96.23 | -87.16 | -578.58 | -278.22 | -235.7 |
Income Tax Expense | 5.42 | 5.79 | -0.32 | -12.69 | -42.51 | -15.14 |
Earnings From Continuing Operations | -135.74 | -102.02 | -86.84 | -565.89 | -235.71 | -220.56 |
Minority Interest in Earnings | 4.55 | -4.89 | -20.51 | 104.25 | -43.7 | 5.82 |
Net Income | -131.19 | -106.9 | -107.36 | -461.64 | -279.41 | -214.74 |
Net Income to Common | -131.19 | -106.9 | -107.36 | -461.64 | -279.41 | -214.74 |
Shares Outstanding (Basic) | 290 | 290 | 290 | 290 | 242 | 266 |
Shares Outstanding (Diluted) | 290 | 290 | 290 | 290 | 242 | 266 |
Shares Change (YoY) | 0.04% | 0.01% | - | 19.99% | -9.09% | 9.99% |
EPS (Basic) | -0.45 | -0.37 | -0.37 | -1.59 | -1.16 | -0.81 |
EPS (Diluted) | -0.45 | -0.37 | -0.37 | -1.59 | -1.16 | -0.81 |
Free Cash Flow | 122.82 | 204.82 | 81.27 | -260.48 | 22.19 | -230.25 |
Free Cash Flow Per Share | 0.42 | 0.71 | 0.28 | -0.90 | 0.09 | -0.87 |
Gross Margin | -3.98% | -0.13% | 8.57% | -47.67% | 9.06% | 7.70% |
Operating Margin | -18.08% | -13.51% | -9.57% | -64.79% | -28.47% | -36.75% |
Profit Margin | -20.05% | -14.73% | -13.39% | -68.85% | -29.57% | -33.66% |
Free Cash Flow Margin | 18.77% | 28.23% | 10.14% | -38.85% | 2.35% | -36.09% |
EBITDA | -75.8 | -56.4 | -38.75 | -401.97 | -254.53 | -220.24 |
EBITDA Margin | -11.59% | -7.77% | -4.83% | -59.95% | -26.94% | -34.52% |
D&A For EBITDA | 42.51 | 41.61 | 37.98 | 32.41 | 14.52 | 14.27 |
EBIT | -118.31 | -98 | -76.72 | -434.38 | -269.05 | -234.52 |
EBIT Margin | -18.08% | -13.51% | -9.57% | -64.79% | -28.47% | -36.75% |
Revenue as Reported | - | - | 801.51 | 670.45 | 944.91 | 638.08 |
Advertising Expenses | - | - | 0.21 | 0.02 | 0.01 | 0.25 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.